Mechanistic models of cancer-immune cycle and immunotherapies
0 comments.
Click here to read/write comments.
Topics:
Authors: Piet van der Graaf
A comparison of two model reduction methodologies for a QSP bone biology system with denosumab dosing
0 comments.
Click here to read/write comments.
Topics:
Clinical validation of a quantitative systems pharmacology (QSP) model for nerve-growth factor (NGF) therapies
0 comments.
Click here to read/write comments.
Topics:
Systems pharmacology modelling of the alternative pathway to study target suitability
0 comments.
Click here to read/write comments.
Topics:
Pharmacokinetics and pharmacodynamics of the novel somatostatin-dopamine chimeric compound BIM23B065 and its metabolite during a growth hormone stimulation test
0 comments.
Click here to read/write comments.
Topics:
Optimize Immuno-oncology Drug Discovery and Development Using Quantitative Systems Pharmacology
Immuno-oncology – The Breakthrough in Cancer Therapeutics Cancer immuno-oncology (IO) uses the body’s natural defenses to combat cancer. These therapies stimulate an individual’s immune system and restore its ability to identify and destroy cancer cells. Anti-cancer immune responses are often inhibited during the spread of cancer. Ultimately, IO therapy expedites long term responses against cancer […]
Read More
0 comments.
Click here to read/write comments.
Topics:
Systems PharmacologyMechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies
0 comments.
Click here to read/write comments.
Topics:
Optimize Immuno-oncology Drug Discovery and Development Using Quantitative Systems Pharmacology
A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to better predict effective drug combinations, especially to more accurately correlate the physiological differences between preclinical models and human patients.
Read More
0 comments.
Click here to read/write comments.
Topics:
The Role of Quantitative Systems Pharmacology in First-in-Human Trial Design
QSP can inform designing First-in-Human clinical trials to help determine the starting dose and subsequent dose escalations to ensure human subject safety.
Read More
0 comments.
Click here to read/write comments.
Topics:
Clinical Pharmacology Strategy, PBPK Modeling & Simulation, PK/PD Modeling & Simulation, Systems PharmacologyModel Informed Quantification of the Feed-Forward Stimulation of Growth Hormone Secretion in Humans
0 comments.
Click here to read/write comments.
Topics:
Improving Clinical Translation of Neuroblastoma Treatment Effects by Integration of Preclinical Experimental Innovation and Computational Modeling
0 comments.
Click here to read/write comments.
Topics:
Managing Immunogenicity Using Quantitative Systems Pharmacology
The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving sector in the biopharmaceutical industry. Biologically-based therapeutic drugs comprise monoclonal antibodies (MAbs), vaccines, recombinant hormones and proteins, antibody-drug conjugates, RNAi, antisense, blood factors, and other large molecules. Although the success of biologics has been demonstrated, there are inherent operational and […]
Read More
0 comments.
Click here to read/write comments.
Topics:
PBPK Modeling & Simulation, PK/PD Modeling & Simulation, Systems PharmacologyDevelopment of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy
0 comments.
Click here to read/write comments.
Topics:
Managing Immunogenicity Using Quantitative Systems Pharmacology
Biologic drug development is a rapidly evolving sector in the biopharmaceutical industry. Immunogenicity is an inherent challenge with this complex class of drugs. A quantitative systems pharmacology approach can be used to predict and better manage immunogenicity, and as a tool to guide clinical and regulatory decision-making in biologics drug development.
Read More
0 comments.
Click here to read/write comments.
Topics:
A Parent-metabolite Pharmacokinetic Model of Paracetamol in Zebrafish
0 comments.
Click here to read/write comments.
Topics:
Quantifying the Growth Hormone Lowering Effect of BIM23B065 After a GH Stimulation Test
0 comments.
Click here to read/write comments.
Topics:
Accuracy of Plasma Clearance Scaling from Adults to Children Using Pathway-specific Covariate Models: A Systematic Investigation Using a Physiologically-based Pharmacokinetic Workflow
0 comments.
Click here to read/write comments.
Topics:
Pharmacokinetics and Pharmacodynamics of the Novel Somatostatin-dopamine Chimeric Compound BIM23B065 and Its Metabolite During a Growth Hormone Stimulation Test
0 comments.
Click here to read/write comments.
Topics:
A Six-stage Workflow for Robust Application of Systems Pharmacology
Quantitative and systems pharmacology (QSP) is increasingly being applied in pharmaceutical research and development. One factor critical to the ultimate success of QSP is the establishment of commonly accepted language, technical criteria, and workflows. We propose an integrated workflow that bridges conceptual objectives with underlying technical detail to support the execution, communication, and evaluation of […]
Read More
0 comments.
Click here to read/write comments.
Topics:
Quantitative Systems Pharmacology Brings Value to Drug Development
Quantitative systems pharmacology (QSP) sits at the interface between pharmacometric modeling and simulation, and systems biology. It uses mathematics to describe biological processes. While pharmacokinetics describes what the body does to the drug, pharmacodynamics quantifies what the drug does to the body; the pharmacological response. QSP is a mechanistic modeling approach and an emerging technology, which mathematically integrates pharmacokinetics, pharmacological response and disease progress/modulation.
Read More
0 comments.
Click here to read/write comments.
Topics: